Paid Clinical Trials in Tampa

Contents

1 Clinical Research in Tampa
2 Clinical Trials For Disease Areas in Tampa
3 Paid Clinical Trials in Tampa
4 Clinical Trials For Health Volunteers in Tampa
5 Medical Discoveries and Innovation in Tampa
6 Why Tampa Is A Great Place For Clinical Research

As a prominent city in Florida, Tampa plays a pivotal role in advancing medical research and innovation. There are multiple different types of studies available to participants, and numerous trial locations throughout the city. Read on to learn more about opportunities to advance medical research.

Clinical Research in Tampa

The clinical studies and research coming out of Tampa is an essential component of the healthcare industry. The knowledge gained serves as a key instrument in progressing medical knowledge. By partnering with research facilities, we are able to connect you with clinical trials in your local area.

Scientists are constantly looking for new ways to treat, detect, and prevent diseases. Every study is dedicated to the patients and helps scientists understand the different health problems and treatment options.

Clinical Trials For Disease Areas in Tampa

Welcome to the forefront of medical research in Tampa, where dedicated professionals are tirelessly working to combat a range of diseases and illnesses. The goal is simple: discover innovative medications that promise a healthier and brighter future.

Tampa General Hospital, for example, has been critical in spearheading medical studies and response efforts for COVID-19. They’ve redefined the landscape of infectious disease treatment and management.

The TGH-USF Health Office of Clinical Research is a leader in fortifying and expanding world-class research. It manages and coordinates clinical trials dedicated to exploring novel approaches in disease prevention, identification, and treatment. This encompasses not only trials related to COVID but a total of approximately 350 research studies. These studies are collaboratively undertaken by Tampa General and USF Health.

Other disease areas are also currently under study in Tampa. From Alzheimer’s to Parkinson’s, scientists are committed to finding new avenues of treatment for such complex neurological illnesses.

Oncology and cancer research are global concerns. Tampa research trials are equally dedicated to finding groundbreaking therapies that can treat these formidable diseases. At Moffitt Cancer Center, patients can receive IP treatments, supportive care, and other treatment options that could potentially improve their quality of life.

You, too, can take a step towards better health. Apply today for a clinical trial in Tampa, FL!

Mucopolysaccharidosis I (MPS I) Registry

NCT00144794

Recruiting

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities. The objectives of the Registry are: * To evaluate the lon... Read More

Gender:

ALL

Ages:

All

Trial Updated:

11/19/2024

Locations: Pediatric Endocrine Associates- Site Number : 840017, Tampa, Florida

Conditions: Mucopolysaccharidosis I (MPS I)

Learn More ›

Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

NCT01060371

Recruiting

Spinocerebellar ataxias (SCA) are genetic neurological diseases that cause imbalance, poor coordination, and speech difficulties. There are different kinds of SCA and this study will focus on types 1, 2,3, and 6 (SCA 1, SCA 2, SCA 3 , also known as Machado-Joseph disease and SCA 6). The diseases are rare, slowly progressive, cause increasingly severe neurological difficulties and are variable across and within genotypes. The purpose of this research study is to bring together a group of experts... Read More

Gender:

ALL

Ages:

6 years and above

Trial Updated:

05/30/2023

Locations: University of South Florida, Tampa, Florida

Conditions: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6

Learn More ›

Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

NCT01574053

Recruiting

Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and b... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/26/2024

Locations: University of South Florida, HDSA Center of Excellence at USF, Tampa, Florida

Conditions: Huntington's Disease

Learn More ›

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

NCT01954992

Recruiting

The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/30/2024

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: Metastatic Pancreatic Adenocarcinoma

Learn More ›

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

NCT02201992

Recruiting

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/29/2024

Locations: Moffitt Cancer Center-International Plaza, Tampa, Florida +2 locations

Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7

Learn More ›

Tamoxifen for Well Differentiated Neurodendocrine Tumors and Hormone Receptor Positive Expression

NCT04123262

Recruiting

This is a single-arm, single-stage clinical study of tamoxifen for patients with well-differentiated neuroendocrine tumors and radiological progression with positive (> 1%) HR (estrogen and/or progesterone) expression by immunohistochemistry (IHC).

Gender:

All

Ages:

18 years and above

Trial Updated:

10/06/2022

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: Neuroendocrine Tumors, Progesterone Receptor Positive Tumor, Estrogen Receptor Positive Tumor

Learn More ›

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT04718818

Recruiting

The present study D5272C00001 (Legacy # 3151-201-008) seeks to evaluate the efficacy and safety of brazikumab versus placebo in patients with moderately to severely active UC and will include assessments of clinical responses as demonstrated by improvement of symptoms and of colonic mucosal appearance as observed on endoscopy.

Gender:

All

Ages:

Between 18 years and 80 years

Trial Updated:

01/19/2021

Locations: Research Site, Tampa, Florida +1 locations

Conditions: Ulcerative Colitis

Learn More ›

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer

NCT05486143

Recruiting

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Condition or disease: Breast Cancer Intervention/treatment: Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib Phase 3

Gender:

All

Ages:

18 years and above

Trial Updated:

08/02/2022

Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Conditions: Breast Cancer

Learn More ›

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT06322693

Recruiting

This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.

Gender:

All

Ages:

18 years and above

Trial Updated:

03/14/2024

Locations: GSK Investigational Site, Tampa, Florida

Conditions: Neoplasms

Learn More ›

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

NCT06399393

Recruiting

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

Gender:

All

Ages:

18 years and above

Trial Updated:

05/01/2024

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: Multiple Myeloma

Learn More ›

Want to try a different medical treatment but can’t afford it? When you take part in paid research studies in Tampa, you earn money for your efforts.

Other than the financial incentive, you can get free medical treatments and exams. With paid clinical trials in Tampa, you are taking an active role in your own healthcare. Since research facilities are offering novel treatments, you can get medications before anyone else.

Your contribution is also helping others. You add valuable data to a pool of information that researchers can use to develop therapies even further. Findings can lead to improvements in healthcare protocols, potentially providing early relief and improved patient outcomes.

Clinical Trials For Health Volunteers in Tampa

Be the Change. Be a Health Hero.

Tampa is calling for healthy volunteers like you to be a part of groundbreaking clinical trials that are shaping the future of medicine. Your involvement has a direct impact on new treatments and interventions that are being evaluated.

Your contribution helps medical professionals and researchers refine healthcare practices. Browse the list below and sign up for a trial that matters to you.

Medical Discoveries and Innovation in Tampa

Many facilities and experts have made notable contributions to the field of medicine. The city fosters a thriving ecosystem of research-focused organizations, including pharmaceutical companies and biotech startups. They create a collaborative environment that drives innovation.

Tampa Medical Innovations, Inc. (TaMI) is a medical device company dedicated to creating simple innovations with broad market potential. They’ve introduced a huge portfolio of products focused on managing high-volume, low-risk needs.

Rachel Feinman, Vice President of Innovation at Tampa General Hospital and Managing Director of TGH Innoventures, was selected as a top leader in cutting-edge healthcare. Innoventures initially started as a $15 million investment fund dedicated to innovation. Mainly in the fields of science, administration, and entrepreneurship.

Why Tampa Is A Great Place For Clinical Research

Tampa’s diverse demographic provides a wide pool of potential participants for clinical trials. According to recent reports, 44.1% of the population is white, 21.8% is black, 17.5% is Hispanic, 4.42% is Asian, and 4.38% is multiracial.

Tampa’s residents have a strong commitment to health and wellness, making them more likely to participate in clinical trials and contribute to the advancement of medical knowledge.

The city’s central location and excellent transportation infrastructure make it easy for both researchers and participants to access and engage in clinical trials. The weather is also pleasant throughout the year, making it easy to collect consistent data and reduce the odds of seasonal variations.